[MCP-1和CCR2在初诊弥漫性大B细胞淋巴瘤中的表达及临床意义]

[Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance].

作者信息

Wang Meng, Zhang Ping-Ping, Zhu Qing, Hu Zhong-Li, Bai Xue, Wu Yan-Ping, Li Jia-Jia

机构信息

The First Affiliated Hospital of Bengbu Medical College, Bengbu 2330000, Anhui Province, China.

Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 2330000, Anhui Province, China.

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):112-119. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.018.

DOI:10.19746/j.cnki.issn.1009-2137.2024.01.018

PMID:38387908

Abstract

OBJECTIVE

To analyze the expression of MCP-1 and CCR2 in newly diagnosed diffuse large B-cell lymphoma (DLBCL), and to evaluate their correlation with clinicopathological features and prognosis.

METHODS

A total of 141 patients with DLBCL diagnosed and treated in the Department of Hematology, the First Affiliated Hospital of Bengbu Medical College from January 2017 to May 2022 were retrospectively collected. The clinical characteristics, pathological data and prognostic factors of the patients were collected. Immunohistochemical staining was used to detect the expression of MCP-1 and CCR2 in the tissues of newly treated DLBCL patients, and to analyze the relationship between MCP-1 and clinical characteristics, prognosis and survival of patients.

RESULTS

The expression of MCP-1 and CCR2 were correlated with Ann Arbor stage, IPI score, lactate dehydrogenase (LDH), Ki-67 index and therapeutic effect. There were no significant correlation between the expression of MCP-1 or CCR2 and other clinical histopathological parameters such as gender, age, β-microglobulin, BCL-2, BCL-6, Hans classification, initial location, B symptoms, bone marrow involvement. There was a statistical difference in OS and PFS between the MCP-1 or CCR2 positive group and the negative group, which was associated to poor prognosis.Univariate Cox regression analysis showed that β-microglobulin, Ki-67 index, IPI score, MCP-1, CCR2 expression levels and disease remission affected the PFS and OS of DLBCL patients ( < 0.05). Gender, age, LDH, BCL-2, BCL-6, Hans classification, primary tumor site, B symptoms, bone marrow involvement, Ann Arbor stage had no effect on PFS and OS ( >0.05). Multivariate analysis showed that β-microglobulin, Ki-67 index, IPI score, MCP-1, CCR2 expression levels and disease remission were independent influencing factors of patients ( < 0.05).

CONCLUSION

The expression rate of MCP-1 or CCR2 in newly treated DLBCL is high, and it is correlated with the clinical features of poor prognosis such as stage and LDH of DLBCL patients, which is a poor prognostic factor affecting PFS and OS.

摘要

目的

分析单核细胞趋化蛋白-1（MCP-1）和C-C趋化因子受体2（CCR2）在新诊断的弥漫性大B细胞淋巴瘤（DLBCL）中的表达情况，并评估其与临床病理特征及预后的相关性。

方法

回顾性收集2017年1月至2022年5月在蚌埠医学院第一附属医院血液科诊断并治疗的141例DLBCL患者。收集患者的临床特征、病理数据及预后因素。采用免疫组织化学染色检测初治DLBCL患者组织中MCP-1和CCR2的表达情况，并分析MCP-1与患者临床特征、预后及生存的关系。

结果

MCP-1和CCR2的表达与Ann Arbor分期、国际预后指数（IPI）评分、乳酸脱氢酶（LDH）、Ki-67指数及治疗效果相关。MCP-1或CCR2的表达与性别、年龄、β2微球蛋白、BCL-2、BCL-6、汉斯分类、原发部位、B症状、骨髓受累等其他临床组织病理学参数之间无显著相关性。MCP-1或CCR2阳性组与阴性组的总生存期（OS）和无进展生存期（PFS）存在统计学差异，提示预后较差。单因素Cox回归分析显示，β2微球蛋白、Ki-67指数、IPI评分、MCP-1、CCR2表达水平及疾病缓解情况影响DLBCL患者的PFS和OS（P<0.05）。性别、年龄、LDH、BCL-2、BCL-6、汉斯分类、原发肿瘤部位、B症状、骨髓受累、Ann Arbor分期对PFS和OS无影响（P>0.05）。多因素分析显示，β2微球蛋白、Ki-67指数、IPI评分、MCP-1、CCR2表达水平及疾病缓解情况是患者的独立影响因素（P<0.05）。